Qilu Pharmaceutical Accelerates Global Commercialization in 2026 with Multiple Product Approvals and Export Milestones

　　【Pharmaceutical Network Enterprise NewsRecently, it was reported that the cyclosporine ophthalmic emulsion developed by Qilu Pharmaceutical has been officially exported to the United States. This drug is a calcineurin inhibitor immunosuppressant, suitable for patients with dry eye syndrome caused by ocular inflammation such as keratoconjunctivitis sicca, whose tear production is suppressed, and for patients who have not observed an increase in tear secretion after using topical anti-inflammatory drugs or undergoing punctal plug insertion.
 

It is reported that on January 21, 2026, the product officially received FDA approval; in February 2026, three batches of commercialized products were successfully produced and passed all quality inspections, achieving immediate production upon approval and meeting standards upon production. Notably, this is Qilu Pharmaceutical Co., Ltd.'s first ophthalmic preparation exported to the United States, as well as the company’s 39th formulation product to enter the U.S. market.
 

In fact, Qilu Pharmaceutical has long adhered to a dual-driven strategy of innovation and internationalization, continuously expanding its presence in the global pharmaceutical market. Currently, its products, including injectables, oral preparations, and ophthalmic formulations across multiple dosage forms and therapeutic areas, have been exported to more than 110 countries and regions worldwide. Dozens of its formulations have successfully entered markets such as the United States, the European Union, and Japan. Statistics show that the company exports approximately 200 million injectable units annually, with 40 products holding leading market shares overseas. In the fiscal year 2025, the company achieved an export value of $1.11 billion.
 

Since 2026, Qilu Pharmaceutical has been actively accelerating its integration into the global pharmaceutical market, continuously expanding its international business footprint with high-quality products and professional services. In addition to cyclosporine ophthalmic emulsion, it has also achieved numerous breakthrough results.
 

On March 10, the broad-spectrum anti-tumor drug Doxorubicin Hydrochloride Liposome Injection, developed and produced by Qilu Pharmaceutical, was successfully shipped and officially sent to the U.S. market. Doxorubicin Hydrochloride Liposome Injection is an innovative formulation of anti-tumor medication prepared using advanced nanotechnology, playing a significant clinical role in the treatment of various solid and hematologic tumors, including ovarian cancer and multiple myeloma.
 

On February 26, Bevacizumab Injection (trade name: Ankevda) developed by Qilu Pharmaceutical received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of various malignant tumors, such as metastatic colorectal cancer, non-small cell lung cancer, breast cancer, renal cancer, ovarian cancer, and cervical cancer. Bevacizumab is a first-line standard treatment drug recommended by multiple NCCN guidelines for non-small cell lung cancer, colorectal cancer, etc. In December 2019, this drug was approved for marketing in China.
 

On January 30, Qilu Pharmaceutical's Ceftriaxone Sodium for Injection and Ganirelix Acetate Injection officially set off to the U.S. market simultaneously from the Qilu High-tech Production Base and the Biomedical Industry Park, respectively.
 

On January 4, a batch of Pertuzumab Injection from Qilu Pharmaceutical was officially shipped from the Biomedical Industry Park, heading to the Middle East market, providing a new treatment option for local HER2-positive breast cancer patients. It is reported that Qilu’s Pertuzumab Injection was approved by the local medical regulatory authority in September 2025 and successfully won the government tender at the end of October.
 

　　……
 

Overall, with its solid quality, Qilu Pharmaceutical is continuously exploring more efficient cross-border trade models and expanding overseas markets. In the future, it will continue to focus on the health needs of global patients, driven by technological innovation and a more open attitude, constantly broadening and deepening its product pipeline to provide globally accessible, affordable, and high-quality "Chinese-made" pharmaceuticals for patients worldwide.
 

　　Disclaimer: In no case shall the information or opinions expressed in this article constitute investment advice to any person.